Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Evidence profile: Chlorfenapyr-pyrethroid ITNs compared to pyrethroid-only ITNs for prevention of malaria.

More »

Table 1 Expand

Table 2.

Evidence profile: Chlorfenapyr-pyrethroid nets compared to pyrethroid-PBO nets for prevention of malaria.

More »

Table 2 Expand

Table 3.

Evidence profile: Pyriproxyfen-pyrethroid nets compared to pyrethroid-only nets for prevention of malaria.

More »

Table 3 Expand

Table 4.

Evidence profile: Pyriproxyfen-pyrethroid nets compared to pyrethroid-PBO nets for prevention of malaria.

More »

Table 4 Expand

Table 5.

Breakdown of reports to studies included in the systematic review.

More »

Table 5 Expand

Fig 1.

PRISMA flow diagram [24].

More »

Fig 1 Expand

Table 6.

Summary characteristics of included studies.

More »

Table 6 Expand

Fig 2.

Risk of bias judgements.

Summarised risk of bias judgements using the Cochrane RoB 2.0 tool for cluster randomised controlled trials. Provided for each study and each outcome where relevant.

More »

Fig 2 Expand

Fig 3.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-only ITNs: Malaria case incidence (overall).

More »

Fig 3 Expand

Fig 4.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-only ITNs: Malaria case incidence (1-year post).

More »

Fig 4 Expand

Fig 5.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-only ITNs: Malaria case incidence (2-year post).

More »

Fig 5 Expand

Fig 6.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (6-months).

More »

Fig 6 Expand

Fig 7.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (12-months).

More »

Fig 7 Expand

Fig 8.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (18-months).

More »

Fig 8 Expand

Fig 9.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (24-months).

More »

Fig 9 Expand

Fig 10.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-PBO ITNs: Malaria case incidence (overall).

More »

Fig 10 Expand

Fig 11.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-PBO ITNs: Malaria case incidence (1-year post).

More »

Fig 11 Expand

Fig 12.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-PBO ITNs: Malaria case incidence (2-year post).

More »

Fig 12 Expand

Fig 13.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-PBO ITNs: Parasite prevalence (12-months).

More »

Fig 13 Expand

Fig 14.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-PBO ITNs: Parasite prevalence (18-months).

More »

Fig 14 Expand

Fig 15.

Chlorfenapyr-pyrethroid ITNs versus pyrethroid-PBO ITNs: Parasite prevalence (24-months).

More »

Fig 15 Expand

Fig 16.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-only ITNs: Malaria case incidence (overall).

More »

Fig 16 Expand

Fig 17.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-only ITNs: Malaria case incidence (1-year post).

More »

Fig 17 Expand

Fig 18.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-only ITNs: Malaria case incidence (2-year post).

More »

Fig 18 Expand

Fig 19.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (6-months).

More »

Fig 19 Expand

Fig 20.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (12-months).

More »

Fig 20 Expand

Fig 21.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (18-months).

More »

Fig 21 Expand

Fig 22.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-only ITNs: Parasite prevalence (24-months).

More »

Fig 22 Expand

Fig 23.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-PBO ITNs: Malaria case incidence (overall).

More »

Fig 23 Expand

Fig 24.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-PBO ITNs: Malaria case incidence (1-year post).

More »

Fig 24 Expand

Fig 25.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-PBO ITNs: Malaria case incidence (2-year post).

More »

Fig 25 Expand

Fig 26.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-PBO ITNs: Parasite prevalence (12-months).

More »

Fig 26 Expand

Fig 27.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-PBO ITNs: Parasite prevalence (18-months).

More »

Fig 27 Expand

Fig 28.

Pyriproxyfen-pyrethroid ITNs versus pyrethroid-PBO ITNs: Parasite prevalence (24-months).

More »

Fig 28 Expand